Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Neoplasms of the CNS

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 180 articles:
HTML format

Single Articles

    June 2020
  1. WANG C, Liu S, Peng L, Zhang K, et al
    Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas.
    BMC Cancer. 2020;20:591.
    PubMed     Abstract available

  2. DING L, Zhang F, He Q, Li Z, et al
    Differentiation of suprasellar meningiomas from non-functioning pituitary macroadenomas by (18)F-FDG and (13)N-Ammonia PET/CT.
    BMC Cancer. 2020;20:564.
    PubMed     Abstract available

  3. LOW SYY, Bte Syed Sulaiman N, Tan EEK, Ng LP, et al
    Cerebrospinal fluid cytokines in metastatic group 3 and 4 medulloblastoma.
    BMC Cancer. 2020;20:554.
    PubMed     Abstract available

  4. CAI Z, Yang S, Li X, Chen F, et al
    Viral infection and glioma: a meta-analysis of prognosis.
    BMC Cancer. 2020;20:549.
    PubMed     Abstract available

    Total DNA methylation as a biomarker of DNA damage and tumor malignancy in intracranial meningiomas.
    BMC Cancer. 2020;20:509.
    PubMed     Abstract available

  6. HOWELL AE, Robinson JW, Wootton RE, McAleenan A, et al
    Testing for causality between systematically identified risk factors and glioma: a Mendelian randomization study.
    BMC Cancer. 2020;20:508.
    PubMed     Abstract available

    May 2020
  7. CORELL A, Ferreyra Vega S, Hoefling N, Carstam L, et al
    The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    BMC Cancer. 2020;20:450.
    PubMed     Abstract available

  8. WHITMIRE P, Rickertsen CR, Hawkins-Daarud A, Carrasco E Jr, et al
    Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients.
    BMC Cancer. 2020;20:447.
    PubMed     Abstract available

  9. KIESEL B, Thome CM, Weiss T, Jakola AS, et al
    Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee.
    BMC Cancer. 2020;20:410.
    PubMed     Abstract available

    April 2020
  10. MITSUYA K, Nakasu Y, Hayashi N, Deguchi S, et al
    Retrospective analysis of salvage surgery for local progression of brain metastasis previously treated with stereotactic irradiation: diagnostic contribution, functional outcome, and prognostic factors.
    BMC Cancer. 2020;20:331.
    PubMed     Abstract available

  11. TAMURA R, Morimoto Y, Kosugi K, Sato M, et al
    Correction to: Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
    BMC Cancer. 2020;20:301.
    PubMed     Abstract available

  12. SHAH N, Liu Z, Tallman RM, Mohammad A, et al
    Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.
    BMC Cancer. 2020;20:292.
    PubMed     Abstract available

  13. FARIA GM, Soares IDP, D'Alincourt Salazar M, Amorim MR, et al
    Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism.
    BMC Cancer. 2020;20:294.
    PubMed     Abstract available

    March 2020
  14. LU C, Liu J, Yao M, Li L, et al
    Downregulation of S100 calcium binding protein A12 inhibits the growth of glioma cells.
    BMC Cancer. 2020;20:261.
    PubMed     Abstract available

  15. WANG L, Ge J, Lan Y, Shi Y, et al
    Tumor mutational burden is associated with poor outcomes in diffuse glioma.
    BMC Cancer. 2020;20:213.
    PubMed     Abstract available

  16. BROWN NF, Ng SM, Brooks C, Coutts T, et al
    A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
    BMC Cancer. 2020;20:198.
    PubMed     Abstract available

  17. TAMURA R, Morimoto Y, Kosugi K, Sato M, et al
    Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
    BMC Cancer. 2020;20:196.
    PubMed     Abstract available

    February 2020
  18. LESUEUR P, Kao W, Leconte A, Geffrelot J, et al
    Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial.
    BMC Cancer. 2020;20:147.
    PubMed     Abstract available

  19. PATRIKIDOU A, Chaigneau L, Isambert N, Kitikidou K, et al
    Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA).
    BMC Cancer. 2020;20:117.
    PubMed     Abstract available

    January 2020
  20. ANG SYL, Lee L, See AAQ, Ang TY, et al
    Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
    BMC Cancer. 2020;20:79.
    PubMed     Abstract available

  21. LIU K, Jiang G, Zhang A, Li Z, et al
    Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
    BMC Cancer. 2020;20:76.
    PubMed     Abstract available

  22. NAKANO T, Aoyama H, Saito H, Tanabe S, et al
    The neurocognitive function change criteria after whole-brain radiation therapy for brain metastasis, in reference to health-related quality of life changes: a prospective observation study.
    BMC Cancer. 2020;20:66.
    PubMed     Abstract available

  23. SRIVASTAVA C, Irshad K, Gupta Y, Sarkar C, et al
    NFsmall ka, CyrillicB is a critical transcriptional regulator of atypical cadherin FAT1 in glioma.
    BMC Cancer. 2020;20:62.
    PubMed     Abstract available

  24. UMPHLETT M, Shea S, Tome-Garcia J, Zhang Y, et al
    Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
    BMC Cancer. 2020;20:47.
    PubMed     Abstract available

  25. LIANG J, Lv X, Lu C, Ye X, et al
    Prognostic factors of patients with Gliomas - an analysis on 335 patients with Glioblastoma and other forms of Gliomas.
    BMC Cancer. 2020;20:35.
    PubMed     Abstract available

  26. GE JJ, Li C, Qi SP, Xue FJ, et al
    Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study.
    BMC Cancer. 2020;20:24.
    PubMed     Abstract available

  27. ENRIQUEZ PEREZ J, Kopecky J, Visse E, Darabi A, et al
    Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
    BMC Cancer. 2020;20:7.
    PubMed     Abstract available

    December 2019
  28. PERREAULT S, Larouche V, Tabori U, Hawkin C, et al
    A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
    BMC Cancer. 2019;19:1250.
    PubMed     Abstract available

  29. SUN C, Dai X, Zhao D, Wang H, et al
    Mesenchymal stem cells promote glioma neovascularization in vivo by fusing with cancer stem cells.
    BMC Cancer. 2019;19:1240.
    PubMed     Abstract available

  30. GANGEMI V, Mignogna C, Guzzi G, Lavano A, et al
    Impact of [(64)Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report.
    BMC Cancer. 2019;19:1197.
    PubMed     Abstract available

  31. DA COSTA AABA, Dos Santos ES, Cotrim DP, Pandolfi NC, et al
    Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis.
    BMC Cancer. 2019;19:1194.
    PubMed     Abstract available

  32. HAO Z, Guo D
    EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study.
    BMC Cancer. 2019;19:1184.
    PubMed     Abstract available

    November 2019
  33. ZHONG QY, Fan EX, Feng GY, Chen QY, et al
    A gene expression-based study on immune cell subtypes and glioma prognosis.
    BMC Cancer. 2019;19:1116.
    PubMed     Abstract available

  34. LI Z, Shen D, Zhang J, Zhang J, et al
    Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis.
    BMC Cancer. 2019;19:1104.
    PubMed     Abstract available

  35. YU W, Ren X, Hu C, Tan Y, et al
    Glioma SOX2 expression decreased after adjuvant therapy.
    BMC Cancer. 2019;19:1087.
    PubMed     Abstract available

  36. SALVUCCI M, Zakaria Z, Carberry S, Tivnan A, et al
    System-based approaches as prognostic tools for glioblastoma.
    BMC Cancer. 2019;19:1092.
    PubMed     Abstract available

  37. CHATURVEDI NK, Mahapatra S, Kesherwani V, Kling MJ, et al
    Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    BMC Cancer. 2019;19:1056.
    PubMed     Abstract available

  38. BAZAN F, Dobi E, Royer B, Curtit E, et al
    Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer.
    BMC Cancer. 2019;19:1029.
    PubMed     Abstract available

    October 2019
  39. CHEN YH, Chen YF, Chen CY, Shih JY, et al
    Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    BMC Cancer. 2019;19:1006.
    PubMed     Abstract available

  40. STOPPEK AK, Kebir S, Junker A, Keyvani K, et al
    Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.
    BMC Cancer. 2019;19:995.
    PubMed     Abstract available

  41. BRITO C, Azevedo A, Esteves S, Marques AR, et al
    Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    BMC Cancer. 2019;19:968.
    PubMed     Abstract available

    September 2019
  42. JANIK K, Treda C, Wlodarczyk A, Peciak J, et al
    A way to understand idiopathic senescence and apoptosis in primary glioblastoma cells - possible approaches to circumvent these phenomena.
    BMC Cancer. 2019;19:923.
    PubMed     Abstract available

  43. JIANG Q, Xie Q, Hu C, Yang Z, et al
    Glioma malignancy is linked to interdependent and inverse AMOG and L1 adhesion molecule expression.
    BMC Cancer. 2019;19:911.
    PubMed     Abstract available

  44. TAKASHIMA Y, Yoshimura T, Kano Y, Hayano A, et al
    Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells.
    BMC Cancer. 2019;19:910.
    PubMed     Abstract available

    August 2019
  45. GOMEZ-ACEVEDO H, Patterson JD, Sardar S, Gokden M, et al
    SMARC-B1 deficient sinonasal carcinoma metastasis to the brain with next generation sequencing data: a case report of perineural invasion progressing to leptomeningeal invasion.
    BMC Cancer. 2019;19:827.
    PubMed     Abstract available

  46. LI X, Meng Y
    Survival analysis of immune-related lncRNA in low-grade glioma.
    BMC Cancer. 2019;19:813.
    PubMed     Abstract available

  47. CHEN Y, Wei J, Cai J, Liu A, et al
    Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
    BMC Cancer. 2019;19:793.
    PubMed     Abstract available

  48. XIAO J, Jin Y, Nie J, Chen F, et al
    Diagnostic and grading accuracy of (18)F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:767.
    PubMed     Abstract available

  49. CHEN JC, Lee IN, Huang C, Wu YP, et al
    Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
    BMC Cancer. 2019;19:756.
    PubMed     Abstract available

    July 2019
  50. IMAIZUMI J, Shida D, Narita Y, Miyakita Y, et al
    Prognostic factors of brain metastases from colorectal cancer.
    BMC Cancer. 2019;19:755.
    PubMed     Abstract available

  51. XI S, Sai K, Hu W, Wang F, et al
    Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
    BMC Cancer. 2019;19:717.
    PubMed     Abstract available

  52. YE T, Wei L, Shi J, Jiang K, et al
    Sirtuin1 activator SRT2183 suppresses glioma cell growth involving activation of endoplasmic reticulum stress pathway.
    BMC Cancer. 2019;19:706.
    PubMed     Abstract available

  53. LIU J, Jin B, Su H, Qu X, et al
    Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    BMC Cancer. 2019;19:702.
    PubMed     Abstract available

    June 2019
  54. SKAGA E, Kulesskiy E, Fayzullin A, Sandberg CJ, et al
    Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naive glioblastoma.
    BMC Cancer. 2019;19:628.
    PubMed     Abstract available

  55. PARK AK, Lee JY, Cheong H, Ramaswamy V, et al
    Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
    BMC Cancer. 2019;19:571.
    PubMed     Abstract available

  56. BUSTAMANTE EDUARDO M, Popovici V, Imboden S, Aebi S, et al
    Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
    BMC Cancer. 2019;19:549.
    PubMed     Abstract available

  57. ZAKRZEWSKA M, Gruszka R, Stawiski K, Fendler W, et al
    Expression-based decision tree model reveals distinct microRNA expression pattern in pediatric neuronal and mixed neuronal-glial tumors.
    BMC Cancer. 2019;19:544.
    PubMed     Abstract available

    May 2019
  58. VAN BUSSEL MTJ, Beijnen JH, Brandsma D
    Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.
    BMC Cancer. 2019;19:519.
    PubMed     Abstract available

  59. LIU CC, Yu CF, Wang SC, Li HY, et al
    Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor.
    BMC Cancer. 2019;19:473.
    PubMed     Abstract available

  60. ZHONG C, Shu M, Ye J, Wang X, et al
    Oncogenic Ras is downregulated by ARHI and induces autophagy by Ras/AKT/mTOR pathway in glioblastoma.
    BMC Cancer. 2019;19:441.
    PubMed     Abstract available

  61. CUNCANNON M, Wong M, Jayamanne D, Guo L, et al
    Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma.
    BMC Cancer. 2019;19:445.
    PubMed     Abstract available

  62. DU N, Bao W, Zhang K, Lu X, et al
    Cytogenetic characterization of the malignant primitive neuroectodermal SK-PN-DW tumor cell line.
    BMC Cancer. 2019;19:412.
    PubMed     Abstract available

    April 2019
  63. KRUG S, Teupe F, Michl P, Gress TM, et al
    Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome.
    BMC Cancer. 2019;19:362.
    PubMed     Abstract available

  64. HE Q, Zhang L, Zhang B, Shi X, et al
    Diagnostic accuracy of (13)N-ammonia PET, (11)C-methionine PET and (18)F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma.
    BMC Cancer. 2019;19:332.
    PubMed     Abstract available

  65. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Horlings HM, et al
    A specific gene expression signature for visceral organ metastasis in breast cancer.
    BMC Cancer. 2019;19:333.
    PubMed     Abstract available

  66. KOPER-LENKIEWICZ OM, Kaminska J, Milewska A, Sawicki K, et al
    Serum and cerebrospinal fluid Neudesin concentration and Neudesin Quotient as potential circulating biomarkers of a primary brain tumor.
    BMC Cancer. 2019;19:319.
    PubMed     Abstract available

  67. COWMAN S, Fan YN, Pizer B, See V, et al
    Decrease of Nibrin expression in chronic hypoxia is associated with hypoxia-induced chemoresistance in some brain tumour cells.
    BMC Cancer. 2019;19:300.
    PubMed     Abstract available

  68. DJUZENOVA CS, Fiedler V, Memmel S, Katzer A, et al
    Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.
    BMC Cancer. 2019;19:299.
    PubMed     Abstract available

    March 2019
  69. SCHORB E, Finke J, Ihorst G, Kasenda B, et al
    Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.
    BMC Cancer. 2019;19:287.
    PubMed     Abstract available

  70. HUA C, Zhao G, Li Y, Bie L, et al
    Correction to: Minichromosome Maintenance (MCM) family as potential diagnostic and prognostic tumor markers for human gliomas.
    BMC Cancer. 2019;19:260.
    PubMed     Abstract available

  71. SUN L, Jin X, Xie L, Xu G, et al
    Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression.
    BMC Cancer. 2019;19:247.
    PubMed     Abstract available

  72. LESUEUR P, Lequesne J, Grellard JM, Dugue A, et al
    Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
    BMC Cancer. 2019;19:198.
    PubMed     Abstract available

  73. KAZLAUSKAS A, Darinskas A, Meskys R, Tamasauskas A, et al
    Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
    BMC Cancer. 2019;19:197.
    PubMed     Abstract available

  74. HICKMANN AK, Frick M, Hadaschik D, Battke F, et al
    Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
    BMC Cancer. 2019;19:192.
    PubMed     Abstract available

  75. HUMMEL S, Kohlmann W, Kollmeyer TM, Jenkins R, et al
    The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database.
    BMC Cancer. 2019;19:190.
    PubMed     Abstract available

    February 2019
  76. LOW SYY, Kuick CH, Seow WY, Bte Syed Sulaiman N, et al
    Primary paediatric epidural sarcomas: molecular exploration of three cases.
    BMC Cancer. 2019;19:182.
    PubMed     Abstract available

  77. LAPRIE A, Ken S, Filleron T, Lubrano V, et al
    Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
    BMC Cancer. 2019;19:167.
    PubMed     Abstract available

  78. OSTROVSKAYA A, Hick C, Hutchinson DS, Stringer BW, et al
    Expression and activity of the calcitonin receptor family in a sample of primary human high-grade gliomas.
    BMC Cancer. 2019;19:157.
    PubMed     Abstract available

  79. LI WY, Zhao TT, Xu HM, Wang ZN, et al
    The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:145.
    PubMed     Abstract available

  80. GE M, Zhan Q, Zhang Z, Ji X, et al
    Different next-generation sequencing pipelines based detection of tumor DNA in cerebrospinal fluid of lung adenocarcinoma cancer patients with leptomeningeal metastases.
    BMC Cancer. 2019;19:143.
    PubMed     Abstract available

  81. STILLER CA, Bayne AM, Chakrabarty A, Kenny T, et al
    Incidence of childhood CNS tumours in Britain and variation in rates by definition of malignant behaviour: population-based study.
    BMC Cancer. 2019;19:139.
    PubMed     Abstract available

  82. WANG J, Chen J
    Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.
    BMC Cancer. 2019;19:131.
    PubMed     Abstract available

  83. KIM TM, Ko YH, Ha SJ, Lee HH, et al
    Impact of in vitro driven expression signatures of CD133 stem cell marker and tumor stroma on clinical outcomes in gastric cancers.
    BMC Cancer. 2019;19:119.
    PubMed     Abstract available

  84. HEYNCKES S, Daka K, Franco P, Gaebelein A, et al
    Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
    BMC Cancer. 2019;19:117.
    PubMed     Abstract available

    January 2019
  85. DARLIX A, Hirtz C, Thezenas S, Maceski A, et al
    The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
    BMC Cancer. 2019;19:110.
    PubMed     Abstract available

  86. ZUO MR, Liang RF, Li M, Xiang YF, et al
    A comprehensive study of risk factors for post-operative pneumonia following resection of meningioma.
    BMC Cancer. 2019;19:100.
    PubMed     Abstract available

  87. GOLDSMITH CS, Kim SM, Karunarathna N, Neuendorff N, et al
    Correction to: inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness.
    BMC Cancer. 2019;19:101.
    PubMed     Abstract available

  88. YIN X, Yan D, Qiu M, Huang L, et al
    Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:95.
    PubMed     Abstract available

  89. LI Z, Mbah NE, Overmeyer JH, Sarver JG, et al
    The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma.
    BMC Cancer. 2019;19:77.
    PubMed     Abstract available

  90. KIM R, Keam B, Kim S, Kim M, et al
    Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    BMC Cancer. 2019;19:19.
    PubMed     Abstract available

    December 2018
  91. TAN WL, Ng QS, Lim C, Tan EH, et al
    Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    BMC Cancer. 2018;18:1288.
    PubMed     Abstract available

  92. FRAZAO L, do Carmo Martins M, Nunes VM, Pimentel J, et al
    BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas.
    BMC Cancer. 2018;18:1259.
    PubMed     Abstract available

  93. MOHAMMAD AS, Adkins CE, Shah N, Aljammal R, et al
    Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer.
    BMC Cancer. 2018;18:1225.
    PubMed     Abstract available

  94. MONNIER A, Boniface R, Bouvet R, Etcheverry A, et al
    The expression of EMX2 lead to cell cycle arrest in glioblastoma cell line.
    BMC Cancer. 2018;18:1213.
    PubMed     Abstract available

  95. LI L, Huang Y, Gao Y, Shi T, et al
    EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
    BMC Cancer. 2018;18:1215.
    PubMed     Abstract available

  96. TAN WL, Ng QS, Lim C, Tan EH, et al
    Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    BMC Cancer. 2018;18:1198.
    PubMed     Abstract available

    November 2018
  97. HWANG K, Lee KS, Choe G, Cho BG, et al
    Secondary glioblastoma after treatment of intracranial germinoma - would radiation-only therapy still be safe? Case report.
    BMC Cancer. 2018;18:1119.
    PubMed     Abstract available

    October 2018
  98. TUNG B, Ma D, Wang S, Oyinlade O, et al
    Kruppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
    BMC Cancer. 2018;18:1025.
    PubMed     Abstract available

  99. AIKO N, Shimokawa T, Miyazaki K, Misumi Y, et al
    Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2018;18:1012.
    PubMed     Abstract available

  100. DA SILVA BB, Eulalio Filho WMN, Costa PVL, Silva RA, et al
    A rare case of primary breast angiosarcoma in a male: a case report.
    BMC Cancer. 2018;18:978.
    PubMed     Abstract available

  101. LORIGUET L, Morisse MC, Dremaux J, Collet L, et al
    Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma.
    BMC Cancer. 2018;18:964.
    PubMed     Abstract available

  102. FOLYOVICH A, Varga V, Varallyay G, Kozak L, et al
    A case report of isolated distal upper extremity weakness due to cerebral metastasis involving the hand knob area.
    BMC Cancer. 2018;18:947.
    PubMed     Abstract available

    September 2018
  103. STRAUBE C, Kessel KA, Schmidt-Graf F, Krieg SM, et al
    A trend towards a more intense adjuvant treatment of low-grade-gliomas in tertiary centers in Germany after RTOG 9802 - results from a multi-center survey.
    BMC Cancer. 2018;18:907.
    PubMed     Abstract available

  104. SONG X, Shu XH, Wu ML, Zheng X, et al
    Postoperative resveratrol administration improves prognosis of rat orthotopic glioblastomas.
    BMC Cancer. 2018;18:871.
    PubMed     Abstract available

  105. MIKKELSEN VE, Stensjoen AL, Granli US, Berntsen EM, et al
    Angiogenesis and radiological tumor growth in patients with glioblastoma.
    BMC Cancer. 2018;18:862.
    PubMed     Abstract available

    August 2018
  106. URUGA H, Moriguchi S, Takahashi Y, Ogawa K, et al
    Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
    BMC Cancer. 2018;18:825.
    PubMed     Abstract available

    July 2018
  107. DU D, Yuan J, Ma W, Ning J, et al
    Clinical significance of FBXO17 gene expression in high-grade glioma.
    BMC Cancer. 2018;18:773.
    PubMed     Abstract available

  108. KIM T, Choi HY, Lee HS, Jung SH, et al
    Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL).
    BMC Cancer. 2018;18:729.
    PubMed     Abstract available

  109. ZHONG C, Chen Y, Tao B, Peng L, et al
    LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway.
    BMC Cancer. 2018;18:722.
    PubMed     Abstract available

    June 2018
  110. VALKONEN M, Haapasalo H, Rilla K, Tyynela-Korhonen K, et al
    Elevated expression of hyaluronan synthase 2 associates with decreased survival in diffusely infiltrating astrocytomas.
    BMC Cancer. 2018;18:664.
    PubMed     Abstract available

  111. POUCHIEU C, Gruber A, Berteaud E, Menegon P, et al
    Increasing incidence of central nervous system (CNS) tumors (2000-2012): findings from a population based registry in Gironde (France).
    BMC Cancer. 2018;18:653.
    PubMed     Abstract available

    May 2018
  112. WANG Y, Guan G, Cheng W, Jiang Y, et al
    ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL.
    BMC Cancer. 2018;18:599.
    PubMed     Abstract available

  113. KARJALAINEN SL, Haapasalo HK, Aspatwar A, Barker H, et al
    Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors.
    BMC Cancer. 2018;18:584.
    PubMed     Abstract available

  114. MARTINI M, de Pascalis I, D'Alessandris QG, Fiorentino V, et al
    VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
    BMC Cancer. 2018;18:553.
    PubMed     Abstract available

  115. GUIDA M, Tommasi S, Strippoli S, Natalicchio MI, et al
    The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
    BMC Cancer. 2018;18:552.
    PubMed     Abstract available

  116. MCDONALD MA, Sanghvi P, Bykowski J, Daniels GA, et al
    Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    BMC Cancer. 2018;18:549.
    PubMed     Abstract available

  117. PEYSER A, Bristow SL, Hershlag A
    Two successful pregnancies following fertility preservation in a patient with anaplastic astrocytoma: a case report.
    BMC Cancer. 2018;18:544.
    PubMed     Abstract available

  118. LEE C, Lee J, Choi SA, Kim SK, et al
    M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas.
    BMC Cancer. 2018;18:535.
    PubMed     Abstract available

  119. SCHULZE M, Hutterer M, Sabo A, Hoja S, et al
    Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditions.
    BMC Cancer. 2018;18:524.
    PubMed     Abstract available

  120. HEGGE B, Sjottem E, Mikkola I
    Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress.
    BMC Cancer. 2018;18:496.
    PubMed     Abstract available

    April 2018
  121. VOSOUGHI E, Lee JM, Miller JR, Nosrati M, et al
    Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
    BMC Cancer. 2018;18:490.
    PubMed     Abstract available

  122. JIN J, Gao Y, Zhang J, Wang L, et al
    Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
    BMC Cancer. 2018;18:446.
    PubMed     Abstract available

  123. LAUBER C, Klink B, Seifert M
    Comparative analysis of histologically classified oligodendrogliomas reveals characteristic molecular differences between subgroups.
    BMC Cancer. 2018;18:399.
    PubMed     Abstract available

  124. CHIO CC, Chen KY, Chang CK, Chuang JY, et al
    Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells.
    BMC Cancer. 2018;18:379.
    PubMed     Abstract available

  125. BOTTCHER MA, Held-Feindt J, Synowitz M, Lucius R, et al
    Modeling treatment-dependent glioma growth including a dormant tumor cell subpopulation.
    BMC Cancer. 2018;18:376.
    PubMed     Abstract available

  126. FATAI AA, Gamieldien J
    A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer.
    BMC Cancer. 2018;18:377.
    PubMed     Abstract available

    March 2018
  127. HUA G, Yanjiao H, Qian L, Jichao W, et al
    Detection of circulating tumor cells in patients with pituitary tumors.
    BMC Cancer. 2018;18:336.
    PubMed     Abstract available

  128. AABERG-JESSEN C, Sorensen MD, Matos ALSA, Moreira JM, et al
    Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.
    BMC Cancer. 2018;18:270.
    PubMed     Abstract available

  129. RANJAN S, Quezado M, Garren N, Boris L, et al
    Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.
    BMC Cancer. 2018;18:239.
    PubMed     Abstract available

    February 2018
  130. HAN Y, Yan LF, Wang XB, Sun YZ, et al
    Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    BMC Cancer. 2018;18:215.
    PubMed     Abstract available

  131. SCHIMMEL WCM, Verhaak E, Hanssens PEJ, Gehring K, et al
    A randomised trial to compare cognitive outcome after gamma knife radiosurgery versus whole brain radiation therapy in patients with multiple brain metastases: research protocol CAR-study B.
    BMC Cancer. 2018;18:218.
    PubMed     Abstract available

  132. JIAO XD, Ding C, Zang YS, Yu G, et al
    Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.
    BMC Cancer. 2018;18:206.
    PubMed     Abstract available

  133. TOTON E, Romaniuk A, Konieczna N, Hofmann J, et al
    Impact of PKCepsilon downregulation on autophagy in glioblastoma cells.
    BMC Cancer. 2018;18:185.
    PubMed     Abstract available

  134. MARITAZ C, Lemare F, Laplanche A, Demirdjian S, et al
    High-dose thiotepa-related neurotoxicity and the role of tramadol in children.
    BMC Cancer. 2018;18:177.
    PubMed     Abstract available

  135. AHN MJ, Lee K, Lee KH, Kim JW, et al
    Combination of anti-PD-1 therapy and stereotactic radiosurgery for a gastric cancer patient with brain metastasis: a case report.
    BMC Cancer. 2018;18:173.
    PubMed     Abstract available

  136. MOREN L, Perryman R, Crook T, Langer JK, et al
    Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.
    BMC Cancer. 2018;18:167.
    PubMed     Abstract available

  137. VASAIKAR S, Tsipras G, Landazuri N, Costa H, et al
    Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?
    BMC Cancer. 2018;18:154.
    PubMed     Abstract available

  138. LIU F, Huang J, Zhang L, Fan F, et al
    Screening for distress in patients with primary brain tumor using distress thermometer: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:124.
    PubMed     Abstract available

    January 2018
  139. EISEMANN T, Costa B, Strelau J, Mittelbronn M, et al
    An advanced glioma cell invasion assay based on organotypic brain slice cultures.
    BMC Cancer. 2018;18:103.
    PubMed     Abstract available

  140. CHOU SY, Yen SL, Huang CC, Huang EY, et al
    Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy.
    BMC Cancer. 2018;18:105.
    PubMed     Abstract available

  141. RICCIARDI GRR, Russo A, Franchina T, Schifano S, et al
    Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    BMC Cancer. 2018;18:97.
    PubMed     Abstract available

  142. GOLDSMITH CS, Kim SM, Karunarathna N, Neuendorff N, et al
    Inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness.
    BMC Cancer. 2018;18:43.
    PubMed     Abstract available

  143. XIA L, Fang C, Chen G, Sun C, et al
    Relationship between the extent of resection and the survival of patients with low-grade gliomas: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:48.
    PubMed     Abstract available

  144. STRAUBE C, Scherb H, Gempt J, Kirschke J, et al
    Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA 17 - ARO 2016/3 - DKTK ROG trial).
    BMC Cancer. 2018;18:15.
    PubMed     Abstract available

    December 2017
  145. CHANG CH, Liu WT, Hung HC, Gean CY, et al
    Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
    BMC Cancer. 2017;17:905.
    PubMed     Abstract available

  146. CONDE M, Michen S, Wiedemuth R, Klink B, et al
    Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells.
    BMC Cancer. 2017;17:889.
    PubMed     Abstract available

    November 2017
  147. YOMO S, Oguchi K
    Prospective study of 11C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment.
    BMC Cancer. 2017;17:713.
    PubMed     Abstract available

    October 2017
  148. TRAN LT, Lai HTM, Koriyama C, Uwatoko F, et al
    The association between high birth weight and the risks of childhood CNS tumors and leukemia: an analysis of a US case-control study in an epidemiological database.
    BMC Cancer. 2017;17:687.
    PubMed     Abstract available

    August 2017
  149. NOH MG, Oh SJ, Ahn EJ, Kim YJ, et al
    Prognostic significance of E-cadherin and N-cadherin expression in Gliomas.
    BMC Cancer. 2017;17:583.
    PubMed     Abstract available

    July 2017
  150. ZINDLER JD, Bruynzeel AME, Eekers DBP, Hurkmans CW, et al
    Whole brain radiotherapy versus stereotactic radiosurgery for 4-10 brain metastases: a phase III randomised multicentre trial.
    BMC Cancer. 2017;17:500.
    PubMed     Abstract available

  151. MIELE E, Po A, Begalli F, Antonucci L, et al
    beta-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells.
    BMC Cancer. 2017;17:488.
    PubMed     Abstract available

    June 2017
  152. WIBROE M, Cappelen J, Castor C, Clausen N, et al
    Cerebellar mutism syndrome in children with brain tumours of the posterior fossa.
    BMC Cancer. 2017;17:439.
    PubMed     Abstract available

  153. HAYASHI N, Takahashi H, Hasegawa Y, Higuchi F, et al
    A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer.
    BMC Cancer. 2017;17:397.
    PubMed     Abstract available

    May 2017
  154. TEYSSONNEAU D, Daste A, Dousset V, Hoepffner JL, et al
    Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
    BMC Cancer. 2017;17:323.
    PubMed     Abstract available

    April 2017
  155. URUP T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, et al
    Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.
    BMC Cancer. 2017;17:278.
    PubMed     Abstract available

  156. TRUBICKA J, Zemojtel T, Hecht J, Falana K, et al
    The germline variants in DNA repair genes in pediatric medulloblastoma: a challenge for current therapeutic strategies.
    BMC Cancer. 2017;17:239.
    PubMed     Abstract available

  157. LI MX, He H, Ruan ZH, Zhu YX, et al
    Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    BMC Cancer. 2017;17:245.
    PubMed     Abstract available

    March 2017
  158. DALAN AB, Gulluoglu S, Tuysuz EC, Kuskucu A, et al
    Simultaneous analysis of miRNA-mRNA in human meningiomas by integrating transcriptome: A relationship between PTX3 and miR-29c.
    BMC Cancer. 2017;17:207.
    PubMed     Abstract available

  159. NARAYAN RS, Fedrigo CA, Brands E, Dik R, et al
    The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
    BMC Cancer. 2017;17:204.
    PubMed     Abstract available

  160. JENSEN SS, Petterson SA, Halle B, Aaberg-Jessen C, et al
    Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo.
    BMC Cancer. 2017;17:178.
    PubMed     Abstract available

    February 2017
  161. PANOSYAN EH, Lin HJ, Koster J, Lasky JL 3rd, et al
    In search of druggable targets for GBM amino acid metabolism.
    BMC Cancer. 2017;17:162.
    PubMed     Abstract available

  162. DEWAN R, Pemov A, Dutra AS, Pak ED, et al
    First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    BMC Cancer. 2017;17:127.
    PubMed     Abstract available

  163. LI Y, Li J, Woo YM, Shen Z, et al
    Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model.
    BMC Cancer. 2017;17:126.
    PubMed     Abstract available

  164. SHANNON S, Jia D, Entersz I, Beelen P, et al
    Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901.
    BMC Cancer. 2017;17:121.
    PubMed     Abstract available

  165. GERSEY ZC, Rodriguez GA, Barbarite E, Sanchez A, et al
    Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species.
    BMC Cancer. 2017;17:99.
    PubMed     Abstract available

    January 2017
  166. DENG X, Zheng Z, Lin B, Su H, et al
    The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    BMC Cancer. 2017;17:42.
    PubMed     Abstract available

  167. RADES D, Janssen S, Dziggel L, Blanck O, et al
    A matched-pair study comparing whole-brain irradiation alone to radiosurgery or fractionated stereotactic radiotherapy alone in patients irradiated for up to three brain metastases.
    BMC Cancer. 2017;17:30.
    PubMed     Abstract available

  168. FROMBERG A, Rabe M, Oppermann H, Gaunitz F, et al
    Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells.
    BMC Cancer. 2017;17:3.
    PubMed     Abstract available

    December 2016
  169. YOMO S, Hayashi M
    Is upfront stereotactic radiosurgery a rational treatment option for very elderly patients with brain metastases? A retrospective analysis of 106 consecutive patients age 80 years and older.
    BMC Cancer. 2016;16:948.
    PubMed     Abstract available

    November 2016
  170. WONG ET, Timmons J, Callahan A, O'Loughlin L, et al
    Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
    BMC Cancer. 2016;16:914.
    PubMed     Abstract available

  171. MUROTA Y, Tabu K, Taga T
    Requirement of ABC transporter inhibition and Hoechst 33342 dye deprivation for the assessment of side population-defined C6 glioma stem cell metabolism using fluorescent probes.
    BMC Cancer. 2016;16:847.
    PubMed     Abstract available

    October 2016
  172. OEHLKE O, Mix M, Graf E, Schimek-Jasch T, et al
    Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
    BMC Cancer. 2016;16:769.
    PubMed     Abstract available

    April 2016
  173. GRAMATZKI D, Roth P, Felsberg J, Hofer S, et al
    Chemotherapy for intracranial ependymoma in adults.
    BMC Cancer. 2016;16:287.
    PubMed     Abstract available

    January 2016
  174. AKIMOTO J, Fukuhara H, Suda T, Nagai K, et al
    Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain.
    BMC Cancer. 2016;16:36.
    PubMed     Abstract available

  175. CHOI SA, Kwak PA, Kim SK, Park SH, et al
    In vivo bioluminescence imaging for leptomeningeal dissemination of medulloblastoma in mouse models.
    BMC Cancer. 2016;16:723.
    PubMed     Abstract available

  176. SCHORB E, Finke J, Ferreri AJ, Ihorst G, et al
    High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma-a randomized phase III trial (MATRix).
    BMC Cancer. 2016;16:282.
    PubMed     Abstract available

  177. NIIBE Y, Nishimura T, Inoue T, Karasawa K, et al
    Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    BMC Cancer. 2016;16:659.
    PubMed     Abstract available

  178. FLECKENSTEIN J, Petroff A, Schafers HJ, Wehler T, et al
    Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    BMC Cancer. 2016;16:348.
    PubMed     Abstract available

  179. KIM S, Nam SJ, Kwon D, Kim H, et al
    MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    BMC Cancer. 2016;16:363.
    PubMed     Abstract available

  180. ANGELINO G, De Pasquale MD, De Sio L, Serra A, et al
    NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications.
    BMC Cancer. 2016;16:512.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.